Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
暂无分享,去创建一个
J. Halter | K. Polonsky | M. Pfeifer | D. Porte | K. Gabbay | J. Jaspan | A. Rubenstein | K S Polonsky | E. Halar | J B Halter | A H Rubenstein | C. Weinberg | D Porte | K H Gabbay | M A Pfeifer | R G Judzewitsch | J B Jaspan | C R Weinberg | E Halar | C Vukadinovic | L Bernstein | M Schneider | K Y Liang | R. Judzewitsch | M. Schneider | D. Porte | C. Vukadinović | L. Bernstein | K. Liang | Kenneth S. Polonsky | Jeffrey B. Halter | A. H. Rubenstein | D. Porte | Roman G. Judzewitsch | Jonathan B. Jaspan | Clarice R. Weinberg | Eugen M. Halar | Michael Pfeifer | Cynthia Vukadinovic | Lawrence Bernstein | Michael Schneider | Kung Yee Liang | Kenneth H. Gabbay | J. B. Jaspan
[1] J. Halter,et al. Diabetic neuropathy and plasma glucose control. , 1981, The American journal of medicine.
[2] M. Peterson,et al. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. , 1979, Metabolism: clinical and experimental.
[3] E. Halar,et al. Nerve conduction velocity measurements: improved accuracy using superimposed response waves. , 1976, Archives of physical medicine and rehabilitation.
[4] A. Culebras,et al. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report. , 1981, Archives of neurology.
[5] Melvin Jl,et al. Sensory and motor conduction velocities in the ulnar and median nerves. , 1966 .
[6] J. Halter,et al. Glycemic control and nerve conduction abnormalities in non-insulin-dependent diabetic subjects. , 1981, Annals of internal medicine.
[7] D. Greene,et al. Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis. , 1976, The New England journal of medicine.
[8] K. Gabbay. Role of sorbitol pathway in neuropathy. , 1973, Advances in metabolic disorders.
[9] K. Gabbay,et al. Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil , 1981, Clinical pharmacology and therapeutics.
[10] P. Dyck,et al. Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry , 1980, Annals of neurology.
[11] J. Kinoshita,et al. Aldose reductase in diabetic cataracts. , 1981, JAMA.
[12] J. Delisa,et al. Nerve conduction velocity: relationship of skin, subcutaneous and intramuscular temperatures. , 1980, Archives of physical medicine and rehabilitation.
[13] K. Gabbay,et al. Aldose reductase inhibition: studies with alrestatin. , 1979, Metabolism: clinical and experimental.
[14] Calvin G. Barnes,et al. Improvement in nerve conduction following treatment in newly diagnosed diabetics. , 1971, Lancet.
[15] J. Kinoshita,et al. Aldose reductase in diabetic complications of the eye. , 1979, Metabolism: clinical and experimental.
[16] B. W. Brown. The crossover experiment for clinical trials. , 1980, Biometrics.
[17] J. Halter,et al. Nerve conduction abnormalities in untreated maturity-onset diabetes: relation to levels of fasting plasma glucose and glycosylated hemoglobin. , 1979, Annals of internal medicine.
[18] J. Kinoshita,et al. Altering the course of cataracts in diabetic rats. , 1980, Investigative ophthalmology & visual science.
[19] P. Gallop,et al. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. , 1977, The Journal of clinical endocrinology and metabolism.
[20] M. Hills,et al. The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.
[21] J. Jakobsen,et al. Early and preventable changes of peripheral nerve structure and function in insulin-deficient diabetic rats. , 1979, Journal of neurology, neurosurgery, and psychiatry.
[22] R. Clements. Diabetic Neuropathy—New Concepts of Its Etiology , 1979, Diabetes.
[23] J. Fagius,et al. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study. , 1981, Journal of neurology, neurosurgery, and psychiatry.